Christopher M Jones1, Aleta Christensen2, R Matthew Gladden2. 1. Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, 200 Independence Ave SW RM434E2, Washington, DC 20201, United States. Electronic address: Christopher.Jones@HHS.GOV. 2. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee, GA 30341, United States.
Abstract
BACKGROUND: The 2015 HIV outbreak in Indiana associated with prescription opioid injection coupled with rising rates of hepatitis C, especially in areas with long-standing opioid abuse, have raised concerns about prescription opioid injection. However, research on this topic is limited. We assessed trends in treatment admissions reporting injection, smoking, and inhalation abuse of prescription opioids and examined characteristics associated with non-oral routes of prescription opioid abuse in the U.S. METHODS: Prescription opioid abuse treatment admissions in the 2004-2013 Treatment Episode Data Set were used to calculate counts and percentages of prescription opioid treatment admissions reporting oral, injection, or smoking/inhalation abuse overall, by sex, age, and race/ethnicity. Multivariable multinomial logistic regression was used to identify demographic and substance use characteristics associated with injection or smoking/inhalation abuse. RESULTS: From 2004-2013, oral abuse decreased from 73.1% to 58.9%; injection abuse increased from 11.7% to 18.1%; and smoking/inhalation abuse increased from 15.3% of admissions to 23.0%. Among treatment admissions, the following were associated with injection abuse: male sex, 18-54 year-olds, non-Hispanic whites, non-Hispanic other, homeless or dependent living, less than full-time work, living in the Midwest or South, ≥1 prior treatment episodes, younger age of first opioid use, and reporting use of cocaine/crack, marijuana, heroin, or methamphetamine. CONCLUSIONS: The proportion of treatment admissions reporting prescription opioid injection and smoking/inhalation abuse increased significantly in the U.S. between 2004 and 2013. Expanding prevention efforts as well as access to medication-assisted treatment and risk reduction services for people who inject drugs is urgently needed. Published by Elsevier B.V.
BACKGROUND: The 2015 HIV outbreak in Indiana associated with prescription opioid injection coupled with rising rates of hepatitis C, especially in areas with long-standing opioid abuse, have raised concerns about prescription opioid injection. However, research on this topic is limited. We assessed trends in treatment admissions reporting injection, smoking, and inhalation abuse of prescription opioids and examined characteristics associated with non-oral routes of prescription opioid abuse in the U.S. METHODS: Prescription opioid abuse treatment admissions in the 2004-2013 Treatment Episode Data Set were used to calculate counts and percentages of prescription opioid treatment admissions reporting oral, injection, or smoking/inhalation abuse overall, by sex, age, and race/ethnicity. Multivariable multinomial logistic regression was used to identify demographic and substance use characteristics associated with injection or smoking/inhalation abuse. RESULTS: From 2004-2013, oral abuse decreased from 73.1% to 58.9%; injection abuse increased from 11.7% to 18.1%; and smoking/inhalation abuse increased from 15.3% of admissions to 23.0%. Among treatment admissions, the following were associated with injection abuse: male sex, 18-54 year-olds, non-Hispanic whites, non-Hispanic other, homeless or dependent living, less than full-time work, living in the Midwest or South, ≥1 prior treatment episodes, younger age of first opioid use, and reporting use of cocaine/crack, marijuana, heroin, or methamphetamine. CONCLUSIONS: The proportion of treatment admissions reporting prescription opioid injection and smoking/inhalation abuse increased significantly in the U.S. between 2004 and 2013. Expanding prevention efforts as well as access to medication-assisted treatment and risk reduction services for people who inject drugs is urgently needed. Published by Elsevier B.V.
Authors: Don C Des Jarlais; Ann Nugent; Alisa Solberg; Jonathan Feelemyer; Jonathan Mermin; Deborah Holtzman Journal: MMWR Morb Mortal Wkly Rep Date: 2015-12-11 Impact factor: 17.586
Authors: Michelle M Van Handel; Charles E Rose; Elaine J Hallisey; Jessica L Kolling; Jon E Zibbell; Brian Lewis; Michele K Bohm; Christopher M Jones; Barry E Flanagan; Azfar-E-Alam Siddiqi; Kashif Iqbal; Andrew L Dent; Jonathan H Mermin; Eugene McCray; John W Ward; John T Brooks Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: David Hyung Won Oh; Alysse Gail Wurcel; David Joseph Tybor; Deirdre Burke; Mariano E Menendez; Matthew Joseph Salzler Journal: Clin Orthop Relat Res Date: 2018-08 Impact factor: 4.176
Authors: Heather Bradley; Elizabeth M Rosenthal; Meredith A Barranco; Tomoko Udo; Patrick S Sullivan; Eli S Rosenberg Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Roman Shrestha; Elizabeth E DiDomizio; Rayne S Kim; Frederick L Altice; Jeffrey A Wickersham; Michael M Copenhaver Journal: J Subst Abuse Treat Date: 2020-06-15